NZ507620A - Use of pyrrolidine-2,5-dione and piperidine-2,6-dione derivatives as mycobacterial (especially tuberculosis) inhibitors - Google Patents

Use of pyrrolidine-2,5-dione and piperidine-2,6-dione derivatives as mycobacterial (especially tuberculosis) inhibitors

Info

Publication number
NZ507620A
NZ507620A NZ507620A NZ50762099A NZ507620A NZ 507620 A NZ507620 A NZ 507620A NZ 507620 A NZ507620 A NZ 507620A NZ 50762099 A NZ50762099 A NZ 50762099A NZ 507620 A NZ507620 A NZ 507620A
Authority
NZ
New Zealand
Prior art keywords
dione
group
alkyl
nonyl
amino
Prior art date
Application number
NZ507620A
Other languages
English (en)
Inventor
Meenakshi Balganesh
Kantharaj Ethirajulu
Babita Singh Ganguly
Ramachandran Janakiraman
Parvinder Kaur
Rangarao Kajipalya
Santosh Nandan
Ramanujulu Pondi Murugappan
Narayanan Ramamurthy
Balasubramanian Venkataraman
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE9802118A external-priority patent/SE9802118D0/xx
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of NZ507620A publication Critical patent/NZ507620A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/45—Non condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyrrole Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
NZ507620A 1998-05-05 1999-05-03 Use of pyrrolidine-2,5-dione and piperidine-2,6-dione derivatives as mycobacterial (especially tuberculosis) inhibitors NZ507620A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN969MA1998 1998-05-05
SE9802118A SE9802118D0 (sv) 1998-06-15 1998-06-15 Mycobacterial inhibitors
PCT/SE1999/000732 WO1999065483A1 (en) 1998-05-05 1999-05-03 Mycobacterial inhibitors

Publications (1)

Publication Number Publication Date
NZ507620A true NZ507620A (en) 2003-05-30

Family

ID=26324850

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ507620A NZ507620A (en) 1998-05-05 1999-05-03 Use of pyrrolidine-2,5-dione and piperidine-2,6-dione derivatives as mycobacterial (especially tuberculosis) inhibitors

Country Status (14)

Country Link
US (1) US6476053B1 (https=)
EP (1) EP1075261B1 (https=)
JP (1) JP2002518324A (https=)
KR (1) KR20010043322A (https=)
CN (1) CN1201735C (https=)
AT (1) ATE322898T1 (https=)
AU (1) AU739140B2 (https=)
BR (1) BR9910185A (https=)
CA (1) CA2330667A1 (https=)
DE (1) DE69930844T2 (https=)
IL (1) IL139144A0 (https=)
NO (1) NO20005548L (https=)
NZ (1) NZ507620A (https=)
WO (1) WO1999065483A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002350115A1 (en) 2001-11-01 2003-05-12 Spectrum Pharmaceuticals, Inc. Medical compositions for intravesical treatment of bladder cancer
KR20080034944A (ko) * 2005-08-19 2008-04-22 아스트라제네카 아베 결핵 치료용 피라졸론 유도체
GB0520368D0 (en) * 2005-10-06 2005-11-16 Univ Aston Antibacterial pyrrols
EP2373617B1 (de) 2008-12-04 2015-02-25 Basf Se Mischungen aus itaconsäure oder itaconsäurederivaten und primären aminen zur herstellung von 1,3- und 1,4-alkylmethylpyrrolidonen
CA3009323C (en) * 2015-12-23 2023-01-24 Henkel Ag & Co. Kgaa Metal working fluid
CN107033060B (zh) * 2017-05-04 2020-01-14 浙江工业大学 一种n-取代顺丁烯二酰亚胺类化合物及其制备与抗菌应用
CN111465611B (zh) * 2017-12-01 2024-10-11 古德T细胞有限公司 预防或治疗脱发的组合物
CN119569636B (zh) * 2024-10-22 2026-03-27 南京吉星生物技术开发有限公司 一种吡咯啉二酮类化合物及其制备方法和杀菌剂应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3883342A (en) * 1973-04-13 1975-05-13 Akzona Inc Plant growth regulators

Also Published As

Publication number Publication date
NO20005548L (no) 2000-12-04
EP1075261A1 (en) 2001-02-14
CN1201735C (zh) 2005-05-18
JP2002518324A (ja) 2002-06-25
NO20005548D0 (no) 2000-11-03
DE69930844D1 (de) 2006-05-24
DE69930844T2 (de) 2006-12-28
CA2330667A1 (en) 1999-12-23
ATE322898T1 (de) 2006-04-15
BR9910185A (pt) 2001-01-09
EP1075261B1 (en) 2006-04-12
US6476053B1 (en) 2002-11-05
IL139144A0 (en) 2001-11-25
AU739140B2 (en) 2001-10-04
WO1999065483A1 (en) 1999-12-23
KR20010043322A (ko) 2001-05-25
CN1308532A (zh) 2001-08-15
AU4304199A (en) 2000-01-05

Similar Documents

Publication Publication Date Title
EP1379507B1 (en) HETEROARYL UREAS CONTAINING NITROGEN HETERO-ATOMS AS p38 KINASE INHIBITORS
DE69322254T2 (de) Pyridyl-substituierte imidazole
JP2963720B2 (ja) 記憶および学習憎進または認知もしくは精神障害治療用のｄ―シクロセリンおよびｄ―アラニン含有組成物
DE69934805T2 (de) Substituierte imidazole mit cytokin-inhibierender wirkung
US7897623B2 (en) ω-carboxyl aryl substituted diphenyl ureas as p38 kinase inhibitors
EP0724570B1 (en) Amidino derivatives useful as nitric oxide synthase inhibitors
JP2022169800A (ja) 細菌の排出ポンプ阻害剤
RU2005113168A (ru) Производные 2-пиридона в качестве ингибитора нейтрофильной эластазы
HUP0401735A2 (hu) CCR1 receptor antagonista hatású piperazinszármazékok és ezeket tartalmazó gyógyászati készítmények
JP2004518628A (ja) 窒素含有化合物およびそれらのグリシン輸送阻害薬としての使用法
CZ283782B6 (cs) 2,4- a 2,5-substituované pyridin-N-oxidy, způsob jejich výroby a jejich použití
KR101021042B1 (ko) 구아닐레이트 사이클라제 활성화제로서의 설포닐아미노카복실산 ｎ-아릴아미드를 포함하는 약제학적 조성물
AU2757399A (en) New use
US6476053B1 (en) Mycobacterial inhibitors
EP2528604B1 (en) Acyl piperidine inhibitors of soluble epoxide hydrolase
DE69919349T2 (de) Piperidinyl- und n-amidinopiperidinyl-derivate
US7491721B2 (en) Antimycobacterial pharmaceutical composition
US4855308A (en) Method of treating senile cognitive decline with N'-substituted aminopyridine adrenergic agents
MXPA00010685A (en) Mycobacterial inhibitors
JP2006523668A (ja) 糖尿病の予防又は治療のためのシクレタニンを含有する相乗作用の薬学的組合せ
JP2007186434A (ja) 医薬組成物
JP3331046B2 (ja) 脳脂質過酸化抑制剤
HK1062440B (en) Heteroaryl ureas containing nitrogen hetero-atoms as p38 kinase inhibitors
JP2003221337A (ja) 酢酸アミド誘導体を有効成分とする痴呆症治療剤
CZ20004294A3 (cs) Deriváty kyseliny hydroxamové jako antibakteriální činidla

Legal Events

Date Code Title Description
RENW Renewal (renewal fees accepted)
PSEA Patent sealed
RENW Renewal (renewal fees accepted)